Calidi Biotherapeutics, Inc.
CLDI- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001855485
No open-market purchases or sales by Calidi Biotherapeutics, Inc. insiders were filed in the last 90 days; 23 institutions reported holding it in 13F filings for Q2 2026, worth $89.3K in total; no superinvestor holds it.
Other share classesCLDWW
Q3 2022 vs. Q2 2022
How the institutions holding Calidi Biotherapeutics, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 42 | 21 | −21 |
| Shares | 20.8M | 3.72M | −17.1M (−82.1%) |
| Value | $205.5M | $36.1M | −$169.5M (−82.4%) |
New holders (9)
Institutions that held Calidi Biotherapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Vivaldi Asset Management, LLC | 400,000 | $3.94M | 0.19% |
| Spartan Fund Management Inc. | 150,000 | $1.48M | 0.45% |
| Logan Stone Capital, LLC | 149,600 | $1.47M | 0.97% |
| Kim, LLC | 100,000 | $985.0K | 0.05% |
| Citadel Advisors LLC | 93,844 | $924.0K | 0.00% |
| Cowen and Company, LLC | 90,624 | $893.0K | 0.09% |
| Virtu Financial LLC | 79,569 | $784.0K | 0.07% |
| Ergoteles LLC | 32,200 | $317.0K | 0.01% |
| HRT Financial LP | 10,918 | $107.0K | 0.00% |
Sold out (30)
Institutions that held Calidi Biotherapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.